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Background. Continuous veno-venous haemodiafiltration is a common form of 
dialysis used in intensive care units. Unfortunately, patients often experience 
hypothermia as a side-effect of the therapy because of the necessity for extracorporeal 
blood flow. Intensive care nurses aim to prevent hypothermia developing. Intravenous 
fluid warmers are sometimes added to the dialysis circuit in an attempt to maintain 
patient temperature. However, the efficacy of this method has not been previously 
studied. 
 
Aim. This paper reports a study to investigate whether intravenous fluid warmers 
prevent hypothermia during continuous veno-venous haemodiafiltration. 
 
Method. A prospective randomized controlled trial was carried out in the intensive 
care unit of a metropolitan, tertiary-referral, teaching hospital. After Ethics 
Committee approval, 60 circuits in continuous veno-venous haemodiafiltration mode 
(200 mL/minute blood flow, 1 L/hour countercurrent dialysate, 3 L/hour pump-
controlled ultrafiltration and prefilter fluid replacement of 1·72·0 L/hour) were 
studied. Circuits were randomized to have either an intravenous fluid warmer set at 
38·5°C on the dialysate and 1 L/hour of replacement fluid lines or no fluid warmer. 
Patient core temperature was recorded at baseline and then hourly. Hypothermia was 
defined as a core temperature <36·0°C. 
 
Results. Mean core temperature loss did not vary between circuits with or without a 
fluid warmer (0·92°C vs. 1·11°C, P = 0·339). Survival analysis found no difference in 
hypothermia incidence between groups (log rank = 0·47, d.f. = 1, P = 0·491). Lower 
baseline temperature (RR 0·142, 95% CI 0·044, 0·459, P = 0·001) and female gender 
(RR 0·185, 95% CI 0·060, 0·573, P = 0·003) were significant risks for hypothermia. 
 
Conclusions. Intravenous fluid warmers used as described do not prevent 
hypothermia during continuous veno-venous haemodiafiltration. Female patients and 
those with a lownormal baseline temperature are most likely to become hypothermic 
during this form of dialysis. Further research is needed to address effective ways of 
preventing hypothermia in critically ill patients receiving continuous renal 
replacement therapies. 
 
What is already known about this topic 
 
Hypothermia is a common complication of continuous renal replacement therapies in 
critically ill patients. 
  
 Hypothermia is an undesirable condition with negative physiological sequelae. 
  
 Continuous veno-venous haemodiafiltration is a frequently used form of continuous 
renal replacement therapies. 
 
 What this paper adds  
 The first data on the efficacy of an intervention (intravenous fluid warmers) to 
prevent hypothermia in patients receiving continuous veno-venous haemodiafiltration. 
  
 Information and quantification regarding risk factors for hypothermia in continuous 
veno-venous haemodiafiltration. 
 
 
 Background 
Up to 25% of intensive care unit (ICU) patients develop acute renal failure (ARF) (de 
Mendonca et al. 2000). Only a small number of these patients have primary renal 
disease with the majority developing ARF secondary to sepsis and septic shock 
(Silvester et al. 2001). Typically, ARF resolves when the underlying diseases abate, 
but until then patients who are unable to remove their own fluid and solute waste, 
require renal dialysis. ICU patients lack the haemodynamic stability necessary to 
undergo the traditional forms of dialysis, which involve the exchange of large 
amounts of fluids over short periods of time. A better result, with fewer 
complications, is achieved through the use of continuous renal replacement therapy 
(CRRT), which involves a slower exchange of fluids over a continuous 24-hour 
period (van Bommel et al. 1994, Holt et al. 1996). 
 
During CRRT, as with other forms of haemodialysis, the patient's blood must leave 
the body and travel over a filter membrane via plastic tubing. This blood is exposed to 
the cooler ambient environment and CRRT fluids, returning to the patient's 
bloodstream at a lower temperature. Experimental work has identified a 1·95·5°C 
drop in blood temperature between the arterial and venous circuit lines of one mode of 
CRRT (continuous veno-venous haemodialysis), with temperature loss increased by 
faster dialysate and/or slower blood flows (Yagi et al. 1998). 
 
The phenomenon of CRRT-related hypothermia is well acknowledged (Ronco 1993, 
Bellomo & Ronco 1999) but little studied. This may be because the therapy is 
relatively new, or because hypothermia is not perceived as a serious complication. 
Although in our setting, temperatures below 36·0°C are interpreted as hypothermia 
and treated, there is no internationally recognized definition and others consider lower 
temperatures acceptable, for example, 35·0°C (Danzl & Pozos 1994, Curley 1995). 
 
The limited research that does exist about hypothermia during CRRT focuses on 
incidence rather than prevention, and is difficult to compare because of the many 
different models of CRRT in use. Arterio-venous CRRT therapies have largely been 
replaced over the past decade by the veno-venous modalities of continuous veno-
venous haemodiafiltration (CVVHDF), continuous veno-venous haemofiltration 
(CVVHF) or continuous veno-venous haemodialysis (CVVHD) (Holt et al. 1996, 
Silvester et al. 2001). 
 
The incidence of hypothermia in patients receiving CRRT has been measured during a 
variety of arterio-venous and veno-venous modalities at 2555%, although definitions 
used for hypothermia have varied (Matamis et al. 1994, Yagi et al. 1998). In one 
report, veno-venous modes were found to have almost twice the incidence of 
hypothermia of arterio-venous regimes (Yagi et al. 1998). No data have been 
published on the incidence of hypothermia specifically in CVVHDF; however, it is 
likely to be as high as or higher than that quoted for other CRRT regimes, because of 
the larger volume of fluid exchange. Other factors identified in prospective clinical 
research as associated with an increased risk for hypothermia during CRRT include an 
increased ultrafiltration rate and the use of muscle relaxants (Matamis et al. 1994). 
 
Although hypothermia is reported to be associated with various forms of CRRT, it is 
surprising that there have been no published evaluations of any of the many 
preventative methods employed. CRRT circuits differ between modes (and even for 
the same mode between hospitals), as do beliefs about appropriate methods to 
preventing and treating CRRT-related hypothermia. 
 
One method used in an attempt to prevent hypothermia is the incorporation of an 
intravenous fluid warmer into the CRRT circuit. These fluid warmers are designed for 
use in intravenous therapy and blood transfusions. However, because the necessary 
tubing can be fitted into CRRT circuits, the practice has gained support from many 
clinicians. Intravenous fluid warmer use with CRRT has never been evaluated for 
effectiveness. However, use on the arterio-venous fistulae of extracorporeal circuits 
has been found effective to treat non-CRRT-related hypothermia (Gentilello et al. 
1990, Gentilello & Moujaes 1995). 
  
  
Significance 
The need to prevent hypothermia in patients receiving CRRT is repeatedly stated in 
the literature (Ronco 1993, Bellomo & Ronco 1999). However, we could find no 
published data on effective ways to achieve this. In our institution, and others, 
intravenous fluid warmers were used semi-regularly but haphazardly and often in 
conjunction with other heating systems in the belief that they might prevent 
CVVHDF-induced hypothermia. As there was no evidence on the efficacy of this 
practice, the following research project was undertaken. 
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Aims 
The aim of the study was to test whether fluid warmers prevent hypothermia in 
patients receiving CVVHDF. 
  
  
Design 
A prospective, randomized controlled clinical trial was conducted. 
  
  
Research setting 
The study was undertaken in the 18-bed intensive care unit of a 700-bed metropolitan, 
tertiary-referral, teaching hospital. The unit has its own nursing staff, a large number 
of whom have ICU qualifications. Over 1400 patients are admitted per annum, and 
have an average length of stay of 4 days. 
  
  
Sample size 
A power calculation determined that the minimum sample size required to detect 
0·5°C difference in temperature loss between the two groups, with 8090% power at 
the 0·05 significance level was 2530 per group. The analysis used data from our 
historical records of a mean temperature loss of 1·0°C in patients undergoing 
CVVHDF, regardless of the presence or absence of a variety of heating therapies 
 
 
Sample 
Sixty CVVHDF circuits were enrolled into the study. A sequential sampling method 
was used to recruit all patients who met the following inclusion criteria: prescribed 
continuous renal replacement therapy according to the unit protocol, at least 18 years 
of age, and a baseline temperature of 36·039·5°C. Patients were not enrolled if they 
met any of the following exclusion criteria: malignant hyperthermia, receiving any 
form of heating or cooling therapy, or a diagnosis of burns. 
  
  
Data collection 
 CVVHDF and fluid warmer protocol 
Each CVVHDF circuit was randomized using a computer generated random number 
system to have a fluid warmer (treatment group) or not (control group). For circuits 
randomized to the treatment group, the 1 L/hour dialysate and 1 L/hour replacement 
fluid lines had warming tubing (Blood and Infusion Warmer Administration Set; 
Biegler Mauerbach, Austria) attached and inserted into the intravenous fluid warmer 
(Biegler Blood and Infusion Warmer BW 485/L, Mauerbach, Austria), according to 
the manufacturer's instructions. The fluid warmer had a standard preset temperature of 
38·5°C. The warming tubing was attached to the dialysate and prefilter replacement 
fluids, not to the blood circuit, and had no impact on the length of the blood circuit. 
This placement was chosen as consistent with preexisting unit practice, as there were 
no published standards or examples of the technique. A standard CVVHDF regime 
was used for all patients, with a blood flow rate of 200 mL/minute, countercurrent 
dialysate rate of 1 L/hour through an AN69 ST (Hospal, Bologna, Italy) hollow fibre 
membrane filter, controlled ultrafiltration rate of 3·0 L/hour and prefilter replacement 
fluids of 1·72·0 L/hour to achieve fluid loss or balance. All dialysis and replacement 
fluid bags (Gambro, Stockholm, Sweden), and a 0·71·0 L/hour replacement fluid line 
were at (air-conditioned) room temperature for patients in both groups. IMED® 
Gemini® infusion pumps (ALARISTM Medical Systems, San Diego, CA, USA) and 
a Gambro BMM-AK10 dialysis pump were used to control the fluid and blood flows 
respectively. Circuits were not anticoagulated. Figure 1 shows the configuration of 
circuits in the experimental group. 
 
Figure 1 CRRT circuit configuration. 
 
 
Patients continued on the same circuit for as long as it remained patent and they 
required the therapy. If the same patient required multiple circuits, then each circuit 
was randomized again if the patient still met all the inclusion criteria and none of the 
exclusion criteria, and at least 1 hour had passed between one circuit being removed 
and the next commencing. 
  
  
Hypothermia data 
Patient core temperature was documented at baseline and then each hour thereafter 
using a rectal or oesophageal catheter probe, which was already in situ as part of 
standard ICU monitoring. The measurement sensitivity was 0·1°C. Patients had one 
cotton bed blanket but were not permitted to have any other form of heating or 
cooling therapy whilst in the study. The ICU was air conditioned at 22·0°C and 
maintained a relatively stable ambient temperature. If hypothermia occurred (defined 
as <36·0°C), the patient was removed from the study and actively rewarmed. 
  
  
Demographic data 
Data were collected on the hours of CVVHDF circuit life and reason for removal (if 
not hypothermia). Data were also collected on patient age, gender, diagnostic group, 
APACHE II score on ICU admission, hours of sedation and paralysis treatment and 
number of CVVHDF circuits used. 
  
  
Ethical considerations 
The Institutional Human Research Ethics Committee and the State Guardianship and 
Administration Tribunal approved the study protocol. The requirement for individual 
consent was waived in consideration of the low-risk nature of the study and the local 
legislative situation of the time, which precluded relatives from giving consent for 
research in unconscious patients. Information about the study was provided to 
patients' relatives, with the option to withdraw from the study without penalty. There 
were no requests for withdrawal. 
  
  
Data analysis 
The primary hypothesis was that the incidence in hypothermia would not be different 
between patients with or without fluid warmers attached to their CVVHDF circuits. 
Because the circuits were used for varying lengths of time, there was also variation in 
the time that they were exposed to the risk of hypothermia. To account for this, the 
primary analysis for difference between groups over time was performed using 
KaplanMeier survival curves with log rank test. Survival was defined as the circuit 
being used for the duration of that dialysis session without the patient developing 
hypothermia. Each circuit was treated as an independent unit of measurement. 
Variables considered risk factors for hypothermia were tested for distribution between 
groups to assess for bias. Proportions were tested with chi-square statistic. Differences 
in mean scores of continuous variables were tested with t-test. Cox Regression 
analysis was performed to test the association of variables with time to hypothermia. 
Variables included use of a fluid warmer, age, gender, baseline temperature, 
APACHE II score, multiple circuits per patient, sedation, and muscle relaxants. A 
significance level of P = 0·05 was used for all comparisons. All analyses wee 
undertaken using the Statistical Package for the Social Sciences (SPSS®, Chicago, IL, 
USA). 
 
 
Results 
Descriptive statistics 
Sixty circuits were randomized into the study from 26 patients. Nine of the circuits 
were excluded from analysis because of protocol violations, one for the use of 
additional warming therapy during the study and eight for non-protocol CVVHDF 
settings, such as larger ultrafiltration rates. Thus, a total of 51 CVVHDF circuits were 
analysed from 24 patients. Of these, 26 circuits were randomized to have a fluid 
warmer attached and 25 to have no fluid warmer. The study groups were well 
matched, with no significant difference for age, gender, APACHE II score on ICU 
admission, diagnostic group and other risk factors for hypothermia (Table 1). 
  
  
Table 1 Sample characteristics 
  Fluid 
warmer 
No fluid 
warmer 
Total P 
value 
Patient age (mean years) (sd) 52·6 (15·4) 53·3 (15·5) 52·9 
(15·3) 
0·88 
Male n (%) 19 (73) 19 (76) 38 (75) 0·81 
Female n (%)  7 (27)  6 (24) 13 (25)   
Study circuit use (hours) (sd) 16·7 (14·4) 15·1 (14·2) 15·9 
(14·2) 
0·69 
Apache II (mean) (sd) 28·2 (8·3) 28·3 (8·5) 28·2 (8·3) 0·94 
Paralysis (n)  4  6 10 0·44 
Sedation (n) 19 19 38 0·81 
Patients with multiple 
circuits (n) 
18 20 38 0·38 
Diagnosis (n)       0·77 
Medical 14 13 27   
Surgical  5  3  8   
Neurological  4  5  9   
Trauma  3  4  7   
Table 1 Sample characteristics 
 
Patient core temperature 
There were no significant differences between groups for mean baseline, minimum or 
maximum temperature or temperature loss during the study (Table 2). 
  
  Fluid warmer No fluid warmer Total P value 
Baseline (mean) 37·49 37·65 37·57 0·41 
Minimum (mean) 36·57 36·54 36·56 0·87 
Temperature loss (mean) 0·92 1·11 1·01 0·34 
Table 2 Patient core temperature data (°C) 
 
 
Reason for completing study 
The study protocol involved a cessation of study involvement if hypothermia 
occurred. There was no difference between groups as to removal from the study for 
the endpoint of hypothermia or for other reasons (Table 3). 
 
  Fluid warmer No fluid warmer Total 
Hypothermia 9 10 19 
Not required 1 2 3 
Patient died 1 0 1 
Circuit failure 12 9 21 
Other 3 4 7 
Table 3 Reason for circuit removal 
  
  
Univariate analysis of survival from hypothermia 
There was no significant difference in the incidence of hypothermia for patients with 
or without a fluid warmer (log rank test = 0·47, d.f. = 1, P = 0·491, Figure 2). The null 
hypothesis was therefore accepted. In order to assess the effect of individual patients 
on the study results, the analysis was also performed for the first circuit per patient 
only (n = 24) and for paired circuits (where an individual patient had a circuit in each 
of the two study groups, n = 28). The results of these analyses were consistent with 
the all circuit analysis, and hypothermia incidence remained not significantly different 
between groups. 
  
 
Figure 2 Survival from hypothermia by fluid warmer (KaplanMeier). 
 
  
Multivariate analysis of survival from hypothermia 
The final model found the two most powerful predictors of hypothermia during 
CVVHDF to be baseline temperature (RR 0·142, 95% CI 0·044, 0·459, P = 0·001) and 
female gender (RR 0·185, 95% CI 0·060, 0·573, P = 0·003). An increase in baseline 
temperature of 1·0°C decreased the risk of being hypothermic by about 86%. 
Alternatively, a decrease of 1·0°C in the baseline temperature increased the risk of 
hypothermia approximately sevenfold. Female gender increased the risk of 
hypothermia by a factor of 5·4. Baseline temperature by gender was not significantly 
different (males 37·57°C, females 37·55°C). 
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Hypothermia is an undesirable complication in patients receiving CRRT. A variety of 
methods are used in attempting to prevent hypothermia, but surprisingly until now 
there has been no published research into which methods are effective, nor their 
comparative value. To our knowledge, this is the first study to evaluate the efficacy of 
using intravenous fluid warmers in the CRRT circuit to prevent therapy-induced 
hypothermia. 
 
Our results suggest that intravenous fluid warmers do not prevent hypothermia in 
patients receiving CVVHDF. The practice of configuring a circuit with a fluid warmer 
involves the costs of the device and the additional disposable equipment and nursing 
time required to undertake the procedure. The additional handling and interruption to 
the circuit also theoretically increases the risk of microbial contamination. If the 
practice of using fluid warmers is abandoned based on this study, there will be 
savings in equipment costs, nursing time, and environmental wastage. 
 
Although we did not find a positive effect from the use of fluid warmers, we note that 
this is the first study into the phenomenon and, as such, the results may be related to 
the study design or sample rather than the treatment itself. The study had 80% power 
to detect a difference of 0·5°C between the groups at P = 0·05. It is possible that a 
larger study might have found a significant difference between groups, but this could 
only have been a difference of 0·5°C or less, which is arguably of negligible clinical 
value. 
 
Patients in the two study groups were well-matched and were strictly monitored for 
adherence to the study protocol. The only known significant difference between the 
two groups was the use of the intravenous fluid warmer on the CVVHDF circuits in 
the treatment group. Our decision to assign the unit of measurement as individual 
circuits rather than patients may have meant that individual patient effects were not 
controlled for, and it also introduced some degree of multicollinearity into our tests. 
However, on restricting the analysis to the first circuit per patient only, or to matched 
pairs (one circuit from each study group per patient), we still did not find a significant 
difference in hypothermia between groups, which gives some support to our method. 
 
Probably the most important factor to consider in the interpretation of these results is 
the influence of the CRRT regime used, that is, CVVHDF. Matamis et al. (1994) 
found that an increased ultrafiltration rate significantly correlated (r = 0·68, P < 0·01) 
with hypothermia in patients receiving the non-dialytic therapies of CAVHF and 
CVVHF. Our ultrafiltration rate of 3 L/hour was relatively high, and the hypothermic 
effect of this, combined with the hypothermic effect of the dialytic counter-current, 
may have outweighed any small protective effect that the fluid warmer could provide. 
The study involved the use of one fluid warmer set at 38·5°C, which incorporated a 
dialysate line at 1 L/hour and a replacement line at 1 L/hour. Additional unwarmed 
replacement fluids were infused at 0·7 L/hour, in the context of a blood flow of 200 
mL/minute and a pump-driven ultrafiltration rate of 3 L/hour. We chose this regime as 
it was the most clinically relevant to our practice. However, other institutions and 
clinicians who prefer different approaches will need to interpret the results in 
consideration of their circuit design and methods. It is entirely possible that some 
variation or variations in the fluid warmer-CRRT circuit set-up would demonstrate 
efficacy in preventing hypothermia, for example, multiple fluid warmers, a different 
brand of fluid warmer, a different temperature setting for the fluid warmer, placement 
of the fluid warmer on a different configuration of fluids, or direct warming of the 
blood tubing itself. Other preventative methods remain untested in the ICU 
population, for example, the microwave heating of fluids that is accepted practice 
during peritoneal dialysis (Armstrong & Zalatan 1992). There is much scope for 
future research to explore this area further. 
 
The gender implication of results was of interest. Nine of 13 circuits from female 
patients (69%) were associated with hypothermia as opposed to only 10 of 38 from 
male patients (26%). This was despite an equivalent baseline temperature by gender 
between circuits. Possibly there was a gender influence of muscle:fat ratios or body 
mass index. Weight data were not available for our study as patients were critically ill 
and bed-bound (fluid management is determined by clinical assessment). Yagi et al. 
(1998) performed a retrospective chart audit of 72 patients who received a variety of 
CRRT modalities and found that lower body weight was significantly associated with 
hypothermia, although the gender component of this was not discussed (Yagi et al. 
1998). 
 
The finding that baseline temperature was the most important risk factor for 
hypothermia was perhaps not surprising. Of the 15 patients whose baseline 
temperature was 37·0°C, 60% developed hypothermia. Incidence decreased to 33% of 
27 patients with a baseline temperature of 37·138·0°C, and 11% of nine patients with 
baseline temperature of 38·1°C. No patients with a baseline temperature of 38·6°C 
became hypothermic. From these results and those of previous studies, it seems that 
CRRT patients can be expected to experience a minimum temperature loss of 
approximately 1·0°C, and therefore patients whose baseline temperature is below 
37·0°C will need to be actively targeted for prevention and early detection of 
hypothermia. Fluid warmers as evaluated in this study will not be beneficial, but a 
multitude of other therapies remain untested and may be useful. 
 
We found the hypothermia incidence in patients on CVVHDF to be 37%. Previous 
studies have reported hypothermic incidence of 55% in CAVHF/CVVHF (Matamis et 
al. 1994), 48% in CVVHD and 40% in CVVHF (Yagi et al. 1998). Our data are 
surprisingly comparable to those in earlier work considering differences in CRRT 
modes and regimes, as well as varying definitions of hypothermia. The dearth of 
studies investigating ways to prevent CRRT-related hypothermia is starkly 
incongruent with the high reported incidence of the phenomenon. 
 
Our patients displayed an average temperature loss of 1·0°C. This figure is artificially 
reduced from that which would have been displayed had we not ceased their study 
participation once core temperature descended below 36·0°C. For example, previous 
studies that did not intervene when patients became hypothermic found higher 
average rates of temperature loss during CRRT of 1·6, 2·4 and 2·6°C (Matamis et al. 
1994, Yagi et al. 1998). This variability is most likely explained by the types of 
CRRT treatments studied (CAVHF/CVVHF, CVVHD and CVVHF, respectively) and 
variation in research designs. In routine clinical (non-research) circumstances, ICU 
staff have been found to be particularly slow to react to hypothermia. A retrospective 
audit of the first admission day for 2362 ICU patients found that 25% of hypothermia 
cases (defined as <35·0°C) were left untreated, and not even noted in patient records 
as a problem (Wilson et al. 1991). 
 
There is currently no consistently accepted definition of hypothermia. The 
recommended diagnostic criterion ranges from a temperature of <35·0°C (Danzl & 
Pozos 1994, Curley 1995) to <36·0°C (Weinberg 1993) or even <36·5°C (Elder 
1984). Hypothermia has deleterious physiological effects stemming from a reduction 
in basal metabolic rate, and can debilitate cardiovascular, oxygenation, coagulation, 
renal, neurological and metabolic functioning, as well as being a subjectively 
unpleasant experience for the patient (Lilly 1990, Weinberg 1993). The extent and 
severity of organ involvement is directly related to the degree of hypothermia, with 
more extreme reductions in temperature for extended periods of time correlating with 
an increase in mortality rate (Curley 1995). 
 
In assessing the appropriate preventative and treatment regimes for hypothermia in 
patients undergoing CRRT, a decision must be made as to what patient temperature is 
considered acceptable. Mild hypothermia is considered relatively harmless and may 
even be beneficial in this population, as the natural compensatory responses to mild 
hypothermia include increases in systemic vascular resistance and cardiac output and 
a decrease in oxygen consumption (Weinberg 1993, Yagi et al. 1998). We chose the 
core temperature point for hypothermia diagnosis and intervention for the study 
protocol as <36·0°C as this generally reflected current opinion and clinical practice in 
our institution. Earlier investigators in this area allowed the temperatures of 20 
CVVHF/CAVHF patients to drop to a much lower mean level of 34·8 ± 0·8°C and 
observed no negative sequelae in oxygenation or haemodynamic parameters (Matamis 
et al. 1994). The heterogeneity of opinion and practice regarding CRRT-related 
hypothermia reflects the current state of the literature: iatrogenic hypothermia is 
largely ignored in favour of prehospital accidental hypothermia leading to hospital 
admission. This is a potentially dangerous situation, as the morbidity and mortality 
risks of hypothermia are not related to aetiology but rather to the temperature itself. 
Iatrogenic forms of hypothermia (including CRRT-related) are known to be under-
recognized, with effective prevention and treatment regimes largely unstudied 
(Wilson et al. 1991, Curley 1995). This is a situation for concern: iatrogenic 
hypothermia should be entirely preventable whilst patients are in our care. 
 
 
Conclusions 
Intravenous fluid warmers do not prevent hypothermia in patients receiving 
CVVHDF. Significant factors for the risk of hypothermia are a low normal baseline 
temperature and female gender. The implications of abandoning the use of fluid 
warmers in this CRRT regime include savings in nursing time, disposable equipment 
costs and environmental waste. Infection risk may also be reduced because of less 
frequent interruption and manipulation of the CRRT circuit. Further research should 
be undertaken on fluid warmers as a possible preventative measure for hypothermia in 
different configurations and with different modes of CRRT. Use as a treatment for 
CRRT-related hypothermia (rather than prevention) is also an unexplored area. Other 
currently used thermoprotective methods also require scientific evaluation. 
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